The Hindu Business Line : Strides' new product gets US nod

Strides Arcolab Ltd has informed the Bombay Stock Exchange that it has received approval for its sixth ANDA (abbreviated new drug application) in the US. The latest product to get the go-ahead is Flumazenil injection used to treat sedative or anaesthesia effects. The product, to be sold as 0.1 mg/ml multiple dose vial, is licensed to Akorn-Strides, LLC, a joint venture formed in 2004. Mr Arun Kumar, Vice-Chairman and Group CEO, said plans were afoot to commercialise the six sterile injectables under the Akorn-Strides partnership. "The approvals reflect yet another significant milestone," he said.- Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Castrol India sets up 100th BikeZone

‘Hero Electric may buy battery packs from any vendor’

Lanco Infratech gets nod for Vizhinjam box terminal project

Forging division hive-off news lifts LG Balakrishnan Brothers

Lafarge emerges front-runner to acquire L&T’s concrete biz

Great Offshore acquisition of Sea Dragon will not be revenue neutral

Lupin embarks on Rs 300-cr expansion

Tax concessions take Macneill to Assam

Lloyd Electric buys Czech company Luvata

Lloyd Electric buyout to help access Europe

Strides' new product gets US nod

GSK Pharma inks deal with Daiichi Sankyo

ONGC-promoted co inks pact

Cash crunch tells on IOC investment plans

Asia MotorWorks looking at bus, LCV foray